Working with TipRanks
Follow Us
Stock Ideas
Daily Updates
Calendars
Education
About Us
Working with TipRanks
Follow Us
MAIA Biotechnology, Inc. (MAIA)
NYSE MKT:MAIA
reports
MAIA Biotechnology, Inc. (MAIA) Stock Price & Analysis
4 Followers
MAIA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.12 - $9.64
Previous Close$2.3
Volume29.02K
Average Volume (3M)56.87K
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)$7.59M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-1.4
Beta0.47
Next Earnings
Aug 21, 2023EPS Estimate
-$0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.64
Shares Outstanding13,625,925
10 Day Avg. Volume28,916
30 Day Avg. Volume56,865
Standard Deviation0.21
R-Squared0.29
Alpha-0.08
Financial Highlights & Ratios
Price to Book (P/B)3.64
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$14.00Price Target Upside508.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
MAIA Biotechnology, Inc. News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MAIA FAQ
What was MAIA Biotechnology, Inc.’s price range in the past 12 months?
MAIA Biotechnology, Inc. lowest stock price was $2.12 and its highest was $9.64 in the past 12 months.
What is MAIA Biotechnology, Inc.’s market cap?
Currently, no data Available
When is MAIA Biotechnology, Inc.’s upcoming earnings report date?
MAIA Biotechnology, Inc.’s upcoming earnings report date is Aug 21, 2023 which is in 83 days.
How were MAIA Biotechnology, Inc.’s earnings last quarter?
MAIA Biotechnology, Inc. released its earnings results on May 08, 2023. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.4 by $0.02.
Is MAIA Biotechnology, Inc. overvalued?
According to Wall Street analysts MAIA Biotechnology, Inc.’s price is currently Undervalued.
Does MAIA Biotechnology, Inc. pay dividends?
MAIA Biotechnology, Inc. does not currently pay dividends.
What is MAIA Biotechnology, Inc.’s EPS estimate?
MAIA Biotechnology, Inc.’s EPS estimate is -$0.38.
How many shares outstanding does MAIA Biotechnology, Inc. have?
MAIA Biotechnology, Inc. has 13,625,925 shares outstanding.
What happened to MAIA Biotechnology, Inc.’s price movement after its last earnings report?
MAIA Biotechnology, Inc. reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.4. Following the earnings report the stock price went down -6.69%.
Which hedge fund is a major shareholder of MAIA Biotechnology, Inc.?
Currently, no hedge funds are holding shares in MAIA
---
MAIA Biotechnology, Inc. Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.00 (508.70% Upside)
$14.00 (508.70% Upside)
Insider Transactions
Bought Shares
Worth $436.9K over
the Last 3 Months
the Last 3 Months
Fundamentals
Return on Equity
-233.70%
Trailing 12-Months
Asset Growth
-20.71%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
MAIA Biotechnology, Inc.
MAIA Biotechnology Inc is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of telomerase-positive cancer cells.
---
Top 5 ETFs holding MAIA
Currently, no data available
Please return soon. This page is being updated.
Up to five ETFs with an Outperform Smart Score that hold MAIA. The ETFs are listed according to market value of MAIA within the ETF
---
Jounce Therapeutics
―
TScan Therapeutics
―
Synaptogenix
―
Protara Therapeutics
―
Unity Biotechnology
―
---